未知机构：国泰海通医药春节期间创新药领域重点新闻梳理上市公司恒瑞医药-20260224

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the innovative pharmaceutical sector, highlighting recent developments and regulatory approvals for various companies in the industry. Company-Specific Developments 恒瑞医药 (Hengrui Medicine) - On February 12, the CDE website indicated that the company submitted a marketing application for ANGPTL3 monoclonal antibody SHR-1918 targeting HOFH. The company has not yet disclosed the Phase III clinical results for SHR-1918 [1] 翰森制药 (Hansoh Pharmaceutical) - On February 20, the company announced that Amivantamab has been approved by the European Medicines Agency (EMA) for marketing in the EU for first-line treatment of EGFR19del or L858R NSCLC, as well as for T790M NSCLC treatment [2] 石药集团 (Shijiazhuang Yiling Pharmaceutical) - On February 16, the company announced that its receptor-biased GLP1/GIP agonist monthly formulation SYH2082 has been approved for clinical trials in the United States [3] 信立泰 (Sino Biopharmaceutical) - On February 12, the company disclosed its initial prospectus for a Hong Kong IPO, updating on R&D progress over the next 12 months, including the Phase II results for JK07 targeting HFrEF expected in 1H26, and the current pipeline status with SAL0147 AT1R/ETAR small molecule, SAL0167 PCSK9 oral cyclic peptide, and SAL012 GPC3 ADC anticipated to advance rapidly to clinical stages [4] 华东医药 (East China Pharmaceutical) - On February 12, the company announced that its self-developed FGFR2b ADC HDM2020 targeting GC/GEJ indications received orphan drug designation from the FDA in the United States [5] - On February 18, a clinical trial was registered for HDM1005 (GLP1R/GIPR weekly formulation) in a head-to-head study against Mars' dulaglutide for second-line diabetes patients in China [6] 康方生物 (CanSino Biologics) - On February 12, the company announced that its PD1CTLA4 dual antibody cardunil combined with chemotherapy is undergoing a Phase III study for first-line gastric cancer [7] - On February 17, a clinical trial was registered for AK104 targeting MSI-H/dMMR colorectal cancer in perioperative treatment in China [8] 中国抗体 (China Antibody) - On February 20, the company disclosed preclinical data for IL17RB monoclonal antibody SM17 targeting CRSwNP and IPF in the journal ERJ OPEN RESEARCH [9] 基石药业 (CStone Pharmaceuticals) - On February 15, PR Newswire reported that the company's PD1VEGF*CTLA4 tri-antibody CS2009 has received FDA approval to initiate a Phase II clinical trial in the United States targeting pan-solid tumors [10] 和铂医药 (HaploX) - On February 23, the company announced that it has licensed the rights for its next-generation CTLA4 monoclonal antibody HBM4003 (with significantly improved safety and expanded therapeutic window) to Solstice Oncology in Greater China. The company will receive a $50 million upfront payment, $50 million in equity, $5 million for recent milestones, and $1.1 billion in subsequent milestones and sales sharing [11]